THE INFLUENCE OF LIRAGLUTIDE ON THE LEVEL OF BLOOD PRESSURE IN PATIENTS WITH ARTERIAL HYPERTENSION AGAINST THE BACKGROUND OF OBESITY AND TYPE 2 DIABETES MELLITUS

Abstract

Objective: To assess the effect of liraglutide (L) on the level of blood pressure (BP) in patients with arterial hypertension (AH) and obesity against the background of type 2 diabetes mellitus (T2DM). Design and method: A total of 55 patients with stage II AH and concomitant non-severe T2DM were examined (fasting plasma glucose <12 mmol/L, glycosylated hemoglobin (HbA1c) - 8.75 ± 1.4%, disease duration 6.4 ± 1.8 years, mean age 51.4 ± 2.7, BMI 35.2 ± 2.6 kg/m2, mean BP 165/103 ± 3.4/2.2 mm Hg). Patients were distributed into 2 groups: the comparison group consisted of 22 patients who received metformin 850 mg 2/day, lisinopril 10 mg 1/day and amlodipine 10 mg 1/day. Patients of the main group (L-group, n = 23), received liraglutide 1.8 mg in addition to similar therapy. Results: 6 months after the initiation of therapy, the following results were obtained: HbA1C in the L group was 6.35 ± 0.5%, and in the comparison group - 7.78 ± 0.45% (p < 0.05). BMI in the L-group was 30.28 ± 1.1 kg/m2, and in the comparison group - 32.5 ± 1.2 kg/m2. Systolic blood pressure (SBP) in the L-group was 132 ± 8.23 mm Hg., and in the comparison group - 143.5 ± 10.15 mm Hg., p < 0.05 of difference between groups. The diastolic blood pressure (DBP) in the L- group was 84.5 ± 3.7 mm Hg, and in the comparison group - 89 ± 5.5 mm Hg, significant differences were not identified. Conclusions: A significant decrease in SBP during treatment with liraglutide in patients with hypertension against the background of obesity and type 2 diabetes can be due to both significant loss of body weight and an improvement of metabolic control. The obtained data suggest that liraglutide has a potential to reduce cardiovascular risk in hypertensive patients with obesity and diabetes.